A clinical trial has found that low-dose interleukin-2 is safe and may significantly extend survival in people with motor ...

A clinical trial has found that low-dose interleukin-2 is both safe and effective for use on people with motor neuron disease ...

Results of the landmark MIROCALS clinical trial, involving researchers from the University of Sheffield, have revealed new ...

The results of the MIROCALS randomized clinical trial have shown that adding low-dose interleukin-2 (IL2LD) to standard ...

Results of the landmark MIROCALS clinical trial, published in The Lancet, show a low-dose interleukin-2 (IL2LD) is safe, ...

ALS (also known as Motor Neuron Disease (MND)) affects around 45,000 people in Europe at any one time. It attacks the nerves ...

Scientists have developed a new test for a biomarker in brain tissue that could detect people who will go on to develop motor neuron disease ... this for much lower amounts of disease proteins ...

The results of the MIROCALS randomised clinical trial showed that adding low-dose interleukin-2 (IL2LD) to standard treatment ...

Results of the MIROCALS (Modifying Immune Responses and Outcomes in ALS) clinical trial are published in The Lancet.

In all, almost 70% of the claimants played in the pack, although there are also 25 former centres, and every position is ...